News

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
STAT5d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
Late last month Moderna suffered a major blow when HHS announced it had canceled grants to the company worth more than $760 million to develop, test, and license a series of mRNA vaccines to ...
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial ...
'Razor blade throat': What to know about COVID-19 variant NB.1.8.1
NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...
pharmaphorum3d
Moderna banks on OpenAI to accelerate mRNA research
In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and ...
pharmaphorum3d
Moderna gets FDA okay for RSV vaccine mResvia
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped ...